Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Non-regulated
MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up:Diuretic response remained nearly normalized, with a mean increase of 326% in six-hour urinary sodium excretion vs baseline All three patients remained on no or low dose loop diuretics, with a reduction of at...
Read More
Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024 Ghent, Belgium – 28 February 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the late-breaking abstract including data from the...
Read More
PRESS RELEASE Acceptance and filing review is a first step in the PMA review process Indicates PMA application is sufficiently complete for in-depth review Received in advance of anticipated timing Ghent, Belgium – 29 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid...
Read More
PRESS RELEASE Strengthens US reimbursement position Builds upon PMA application submitted to the US FDA on 27 December 2023 Ghent, Belgium – 03 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that...
Read More
Ghent, Belgium – 6 September 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its half-year results ended 30 June 2023 on Thursday, 14 September 2023. The management team will host a conference call...
Read More
US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces...
Read More
Extensive real world alfapump experience derisks planned US & Canadian launch Strong clinical alfapump profile demonstrated in North American POSEIDON study All approvals received to commence US MOJAVE study of DSR 2.0 Ghent, Belgium – 06 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment...
Read More
Poster presentation at EASL by Dr. Florence Wong on 21 June 2023; selected for additional poster presentation on 23 June 2023 Conference call with live webcast by Sequana Medical on 21 June 2023 at 03:00 pm CEST / 09:00 am EST Ghent, Belgium – 19 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA, the...
Read More
Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that its alfapump has won the ‘Best Technology’ Award at the European Mediscience Awards in London last night.   The...
Read More
PRESS RELEASE   MOJAVE study on track to start in Q2 2023 as planned, with initial data by year-end Randomized, controlled study in US seeking to confirm strong efficacy data seen in RED DESERT and SAHARA studies DSR well positioned as disease-modifying heart failure therapy Ghent, Belgium – 02 May 2023 – Sequana Medical NV...
Read More
1 2 3 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES